Linus Pauling and Vitamin C for the Common Cold

Table of Contents

  1. Overview
  2. What Pauling Claimed
  3. The 1970s Trials the Book Set Off
  4. What Randomized Trials Actually Show
  5. The Exception Pauling Got Right
  6. Why the Story Went Wrong
  7. Practical Dosing Today
  8. Safety
  9. Key Research Papers
  10. Connections
  11. Featured Videos

1. Overview

In 1970, Linus Pauling — already a Nobel laureate in chemistry and winner of the Nobel Peace Prize, and by any measure one of the most influential scientists of the twentieth century — published a short popular book called Vitamin C and the Common Cold (W. H. Freeman). Its message was simple and electrifying: a cheap, safe vitamin, taken in doses far beyond anything found in food, could largely prevent the most common illness on Earth — and stop a cold in its tracks if you caught one anyway.

The book became a bestseller almost immediately. Pharmacies sold out of vitamin C; within a few years a large share of American households had tried megadose ascorbic acid for colds, and “take vitamin C” became — and remains — one of the most widely followed pieces of folk-medical advice in the world. It is fair to say that no single publication has done more to shape public behavior around a vitamin.

The book also started a scientific fight that has never fully ended. Was Pauling right? The honest answer, five decades and dozens of randomized trials later, is: mostly no, partly yes. Regular vitamin C does not prevent colds for ordinary people — that central claim failed when tested. But it does modestly shorten colds, the effect is real and reproducible, and in one specific situation — people under heavy short-term physical stress — the prevention claim held up remarkably well. This page walks through what Pauling actually said, what the trials found, where he was wrong, where his critics overcorrected, and what a practical reader should do with all of it.

2. What Pauling Claimed

Pauling's recommendation in the 1970 book was that most people take 1 to 2 grams of vitamin C per day, or more — roughly 10 to 20 times the intake needed to prevent scurvy — as a routine preventive measure, and increase the dose further at the first sign of a cold to abort it. He argued that individual needs varied widely, that the official recommended allowances were set far too low, and that humanity's inability to make its own vitamin C (most animals synthesize it internally) left us chronically short of an optimal intake. This reasoning grew out of the broader framework he called orthomolecular medicine — treating disease by adjusting concentrations of substances naturally present in the body.

When scientists objected that the evidence was thin, Pauling did not retreat — he doubled down in the formal literature. In 1971 he published two defenses: a paper in the Proceedings of the National Academy of Sciences re-analyzing the existing placebo-controlled trials and arguing that they showed a statistically significant protective effect that reviewers had wrongly dismissed, and a review in the American Journal of Clinical Nutrition laying out the case in full. Both are linked in the Key Research Papers below, and both are worth reading today as examples of a brilliant scientist arguing hard from limited data.

A detail with real irony, worth flagging now: the trial Pauling leaned on hardest in his PNAS analysis was a Swiss study of schoolchildren at a ski camp — children under cold exposure and heavy exertion. That is precisely the special situation in which later evidence shows vitamin C genuinely does prevent colds (section 5). Pauling's error was not that his favorite trial was wrong; it was generalizing from skiers in the Alps to everyone, everywhere, all winter.

Evidence label for the claims as stated: the prevention claim for the general population was a bold extrapolation ahead of the data and was later contradicted by randomized trials; the “abort a cold once started” claim has never been consistently demonstrated; the duration claim — colds get somewhat shorter — turned out to be correct.

3. The 1970s Trials the Book Set Off

One genuine service the book performed: it provoked the large, careful trials that had never been done. Two deserve special mention, because between them they set the tone for everything after.

The Toronto trial (Anderson, Reid & Beaton, 1972). Canadian researchers ran a large double-blind, placebo-controlled trial through a winter specifically to test the book's claims, using prophylactic daily vitamin C with extra doses at cold onset. The result was a partial surprise on both sides: the vitamin group did not have meaningfully fewer colds — the dramatic prevention Pauling predicted did not appear — but they spent modestly fewer days confined indoors and off work. In other words, colds were not prevented, but they seemed a bit milder. That two-part pattern — no prevention, modest softening — is essentially what the accumulated evidence still shows today.

The NIH trial (Karlowski and colleagues, 1975). A double-blind trial in employees at the National Institutes of Health used multi-gram daily prophylaxis plus additional therapeutic doses during colds. It found small reductions in cold duration and severity — but the authors then reported that many participants had tasted their capsules and guessed whether they were on vitamin C or placebo (ascorbic acid is sour; the placebo was not), and when they analyzed by who had guessed correctly, the apparent benefit shrank. They concluded the effect might be largely placebo. This “broken blind” became one of the most cited arguments against vitamin C for decades. It is worth knowing that the story did not end there: Harri Hemilä — the University of Helsinki researcher who went on to lead the Cochrane reviews on this topic — later published detailed critiques arguing that the Karlowski subgroup analysis was itself statistically unsound, and that the trial's raw finding of a modest duration benefit was consistent with everything found since. The point is not that either side was dishonest; it is that a modest, real effect is exactly the kind that small trials and subgroup arguments can argue in and out of existence.

Evidence label: these are real randomized trials, the strongest design available — but individually small by modern standards. The reliable picture comes from pooling all of them, which is the next section.

4. What Randomized Trials Actually Show

The definitive summary of this literature is the Cochrane systematic review by Hemilä and Chalker (2013), which pooled every placebo-controlled trial using at least 0.2 g/day of vitamin C. Cochrane reviews are the closest thing evidence-based medicine has to a final scorecard, and this one is unusually clear. Its findings, claim by claim:

Evidence label: high. This is a Cochrane meta-analysis of several dozen randomized placebo-controlled trials conducted over 60+ years — the strongest tier of clinical evidence that exists for a question like this. For a broader look at vitamin C's role in immune function beyond colds, see Vitamin C & Immune Function.

5. The Exception Pauling Got Right

Buried inside the same Cochrane review is the finding that vindicates a narrow version of Pauling's claim — and it traces straight back to that Swiss ski camp. Five trials enrolled people undergoing short periods of extreme physical stress: marathon runners, competitive skiers, and soldiers on subarctic winter exercises. In those 598 participants, prophylactic vitamin C roughly halved the number of colds — pooled risk ratio 0.48 (95% CI 0.35 to 0.64). That is a large, statistically solid effect, and it is the same population Pauling's favorite 1971 evidence came from.

Why would the vitamin work for a marathoner and not for the rest of us? The most common explanation is that severe exertion and cold exposure temporarily suppress immune defenses and burn through the body's ascorbate faster — heavy exercise is an oxidative and hormonal stress — so a person who is briefly, functionally short of vitamin C gets real protection from topping up, while a person whose tissues are already saturated gets nothing extra. That mechanism is plausible but not proven; what is well established is the trial result itself.

What this means practically: if you are about to run a marathon, race ski, or spend weeks doing hard physical work in the cold, prophylactic vitamin C (the stress trials used roughly 0.25 to 1 g/day) has genuinely good evidence for cutting your cold risk. If you are commuting to an office, it does not. Evidence label: high for this specific subgroup — consistent across five trials — but note the subgroup is narrow, and “I feel stressed at work” is not the kind of stress these trials studied.

6. Why the Story Went Wrong

The vitamin C saga is now taught as a case study in how science communication fails, and both sides of the failure are instructive.

Where Pauling failed: he made a confident universal claim to the public before the decisive trials existed, resting on a handful of small studies — several of which, like the ski-camp trial, came from special populations that did not represent ordinary life. When the big trials came back mixed, he read them selectively, emphasizing every positive subgroup and re-analyzing away every null result. His enormous personal authority — this was a man with two Nobel Prizes — meant the public heard certainty where the evidence held only a hint. And the pattern repeated: in the late 1970s he extended similar ahead-of-the-data confidence to vitamin C and cancer, a story with a harder landing, told on our Vitamin C & Cancer page.

Where his critics overcorrected: “Pauling was completely debunked” is itself an overstatement, and repeating it requires ignoring the same Cochrane review that sank the prevention claim. The duration effect is real: it has held up across dozens of trials, it is larger in children, and vitamin C at these doses is cheap and, for most people, safe. The physical-stress prevention effect is not just real but large. A fair verdict is that Pauling took a genuine, modest, situation-dependent effect and inflated it into a universal one — which is a very different failure from championing something that does nothing. Few daily supplements can claim even a reproducible half-day off a cold.

There is also a systemic lesson: for decades, both enthusiasts and skeptics treated this as a yes/no question — either vitamin C “works” or it “doesn't.” The actual answer — no for preventing colds in ordinary life, yes for shortening them slightly, yes for preventing them under extreme exertion, no for treating them once started — is more conditional than either camp wanted, and it took half a century of trials to say it with confidence.

7. Practical Dosing Today

What does a reasonable, evidence-minded person do with all this?

8. Safety

Vitamin C is among the safest supplements at moderate doses, but Pauling-scale intakes have documented harms, and they belong right beside the claims:

None of this makes vitamin C dangerous at the 100–200 mg/day found in a produce-rich diet; the cautions scale with the dose, which is exactly why megadose advice deserves more scrutiny than food-level advice.

9. Key Research Papers

  1. Pauling L. The significance of the evidence about ascorbic acid and the common cold. Proc Natl Acad Sci USA 1971;68(11):2678-81
  2. Pauling L. Ascorbic acid and the common cold. Am J Clin Nutr 1971;24(11):1294-9
  3. Anderson TW, Reid DB, Beaton GH. Vitamin C and the common cold: a double-blind trial. Can Med Assoc J 1972;107(6):503-8
  4. Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM. Ascorbic acid for the common cold. A prophylactic and therapeutic trial. JAMA 1975;231(10):1038-42
  5. Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev 2013;2013(1):CD000980
  6. Padayatty SJ, Sun H, Wang Y, Riordan HD, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004;140(7):533-7
  7. Hemilä H. Vitamin C and infections. Nutrients 2017;9(4):339

Live PubMed Searches

  1. Vitamin C and the common cold
  2. Ascorbic acid cold prophylaxis — randomized trials
  3. Vitamin C for colds in children
  4. Vitamin C, physical stress, and respiratory infection
  5. Ascorbic acid pharmacokinetics — oral vs intravenous

Connections

Back to Table of Contents